NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in development for the treatment of chronic pain. NYX-2925 is currently being evaluated in multiple Phase 2 studies in patients with fibromyalgia and painful diabetic peripheral neuropathy (DPN).
NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain. It is established that, when pain becomes chronic, it can become a largely centralized disorder mediated by central learning and memory processes. We believe NYX-2925, by enhancing neural cell communication, has the potential to address a wide range of chronic pain conditions, including fibromyalgia, painful DPN, and other centralized chronic pain conditions.
In clinical studies, NYX-2925 has been shown to have activity that affects central pain processing, resulting in alleviation of pain and other symptoms associated with chronic pain conditions. In preclinical models of numerous neuropathic pain conditions, NYX-2925 has shown robust analgesic activity. Across these preclinical studies, as well as in Phase 1 and Phase 2 clinical studies, NYX-2925 has exhibited a favorable safety and tolerability profile across a wide dose range. In April 2019, we reported detailed results from a Phase 2 study in patients with painful DPN, demonstrating robust analgesic activity in patients with advanced (more chronic) DPN. In early June 2019, we reported positive top-line data from a Phase 2 study of NYX-2925 in patients with fibromyalgia, demonstrating significant effects on both biomarkers and patient-reported outcomes.
The U.S. Food and Drug Administration has granted Fast Track designation to the development of NYX-2925 for the treatment of neuropathic pain associated with DPN. We believe the therapeutic profile of NYX-2925 will allow us to expand the development of this molecule into multiple other chronic pain conditions.
See the Clinical Studies page to learn more about ongoing studies with NYX-2925.